Home Biosimilar Antibodies Immunology & Inflammation IL Receptor Tozorakimab (Anti-IL-33)
For research use only. Not for use in humans.

Tozorakimab (Anti-IL-33)

Synonyms: IL-33,DVS27

Tozorakimab (Anti-IL-33) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. It can be used to research chronic obstructive pulmonary disease. MW :144.54 KD.

Tozorakimab (Anti-IL-33)

Quality Control

Batch: Purity: 99% Protein concentration: 5.329mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Tozorakimab (Anti-IL-33) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. It can be used to research chronic obstructive pulmonary disease. MW :144.54 KD.
References

Product Details

CAS No. 2376858-66-9
Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07566195 RECRUITING Drug: Tozorakimab Dose Regimen 1|Drug: Tozorakimab Dose Regi Chronic Obstructive Pulmonary Disease; COPD AstraZeneca 2026-05-05 PHASE3
NCT05624450 RECRUITING Drug: Tozorakimab|Drug: Placebo Viral Lung Infection and Acute Respiratory Failure AstraZeneca 2022-12-13 PHASE3
NCT06932263 RECRUITING Drug: Tozorakimab|Drug: Placebo Asthma AstraZeneca 2025-03-26 PHASE2
NCT06897748 COMPLETED Drug: Placebo|Drug: Tozorakimab Chronic Obstructive Pulmonary Disease (COPD) AstraZeneca 2025-04-12 PHASE2
NCT06040086 COMPLETED Drug: Placebo|Drug: Tozorakimab Chronic Obstructive Pulmonary Disease (COPD) AstraZeneca 2023-09-22 PHASE3
NCT05742802 COMPLETED Chronic Obstructive Pulmonary Disease (COPD) AstraZeneca 2023-03-06 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-27)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.